STE Steris (STE) Insider Trading, Ownership & Congress Trades
Medical Devices · Orthopedic, prosthetic & surgical appliances & supplies · CIK 0001757898
Congress · 2Form 144 · 2
Insider buyers, 180 days
0
Funds added, last quarter
412
13F, latest reported quarter
Conversions, 180 days
4
Codes C/M, not in net · $903.7K priced
What the filings say about STE
Insiders, 180 days
-$2.5M net sold
4 sellers · 0% of sales under a 10b5-1 plan
Congress, 1 year
2 bought · 3 sold
Latest: sale, 2026-09-15
Planned sales (Form 144), 90 days
$1.9M
2 notices
Steris insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, STERIS plc insiders sold a net $2.5M of stock across 68 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Aug 11, 2025.
- The trade is 16.7% of the 24,305 shares held after it.
- No other insider sold within 30 days.
- 412 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Sohi Mohsen sold about $956.8K of STE on Aug 12, 2026; 412 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Nov 11, 2025.
- The trade is 4.0% of the 35,259 shares held after it.
- 2 other insiders sold within 30 days.
- 412 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Sr. VP, Gen Counsel, and Sec. Zangerle John Adam sold about $297.0K of STE on Jun 15, 2026; 2 other insiders sold within 30 days and 412 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Jun 4, 2026.
- The trade is 2.2% of the 63,647 shares held after it.
- 2 other insiders sold within 30 days.
- 412 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Carestio Daniel A sold about $291.3K of STE on Jun 5, 2026; 2 other insiders sold within 30 days and 412 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Oct 6, 2025.
- The trade is 4.7% of the 65,021 shares held after it.
- 2 other insiders sold within 30 days.
- 412 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Carestio Daniel A sold about $655.5K of STE on Jun 4, 2026; 2 other insiders sold within 30 days and 412 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on May 16, 2023.
- The trade is 3.8% of the 38,964 shares held after it.
- 2 other insiders sold within 30 days.
- 412 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Breeden Richard C sold about $310.3K of STE on Jun 2, 2026; 2 other insiders sold within 30 days and 412 funds added in the latest 13F quarter.68 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$2.5M over 180 days
-$956.8K over 90 days
below 71% of Medical Devices
Congress
2 members bought in the last year
more than 81% of Medical Devices
Funds
412 funds bought in last quarter
more than 93% of Medical Devices
Revenue
+8.7% year over year
below 52% of Medical Devices
Margin
13.2% net margin
more than 86% of Medical Devices
Buybacks
$115.5M repurchased, FY to 2026-06-30
more than 64% of Medical Devices
Short interest
2.9% of the float short (float per yahoo 2026-10-26) · 4.2 days to cover · settled 2026-09-30
below 56% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch STE
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-4.3%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns STE: institutional holders (13F)
13F holdings, latest reported quarter
8,820,889 sh
$1.9B
6,406,906 sh
$1.3B
5,072,818 sh
$1.1B
5,001,950 sh
$1.1B
3,801,077 sh
$850.4M
Congress trades in STE
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2026-09-15 · disclosed 10 days later
$15,001 - $50,000
Sold 2026-08-25 · disclosed 15 days later
$100,001 - $250,000
Sold 2026-07-31 · disclosed 3 days later
$1,001 - $15,000
Sold 2026-07-29 · disclosed 5 days later
$1,001 - $15,000
Sold 2026-07-27 · disclosed 7 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
STE planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Breeden Richard C
Filed 2026-08-18
$953.1K
Sohi Mohsen
Filed 2026-08-12
$956.8K
STE mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
FAM DIVIDEND FOCUS FUND
$25.0M position · as of 2026-06-30
3.9%
Tandem Fund
$526.4K position · as of 2026-06-30
3.4%
iShares U.S. Medical Devices ETF
$96.7M position · as of 2026-06-30
3.2%
Touchstone Funds Group Trust-Touchstone Mid Cap Fund
$122.1M position · as of 2026-06-30
2.7%
Eventide Dividend Opportunities Fund
$30.5M position · as of 2026-06-30
2.1%
Small-MidCap Dividend Income Fund
$30.4M position · as of 2026-05-31
2.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Government contracts
Award ceilings over the contract's life, subsidiaries included.
Not annual revenue (USASpending.gov).
Department Of Veterans Affairs
RENTAL OF A MOBILE STERILE PROCESSING DEPARTMENT · 2021-11-01
$5.5M
Federal awards ≥ $25M in the last 90 days, matched via the SAM.gov parent registry
Corporate PAC
The company's PAC: committee totals only, never individual donors (FEC).
Steris Corporation Employee Political Action Committee (A.K.A. Steris Employee Pac)
Cycle 2026 · $84K spent
$103.5K
Federal Election Commission, matched by the PAC's connected organisation
Executive pay vs shareholder return · Daniel J.Carestio
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$11.5M
$3.3M
$2.6M
+21%
+7%
2024
$10.7M
$7.9M
$2.6M
+23%
+23%
2023
$9.6M
$14.1M
$2.5M
+20%
+15%
2022
$7.7M
$2.2M
$2.1M
+2%
-1%
2020
$6.8M
$20.0M
$2.3M
+37%
+67%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $2.5M sold by insiders over 180 days, 412 funds added last quarter, 2 House member(s) bought in 12 months, disclosed weeks after the trade, $1.9M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
STE financials
Revenue growth
+8.7%
XBRL, annual
Net margin
13.2%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$6.0B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM STE
| FY Mar 2026 | $5.9B |
| FY Mar 2025 | $5.5B |
| FY Mar 2024 | n/a |
| FY Mar 2023 | n/a |
| FY Mar 2022 | $4.6B |
| Jun 2026 | $1.5B |
| Mar 2026 | $1.6B |
| Dec 2025 | $1.5B |
| Sep 2025 | $1.5B |
| Jun 2025 | $1.4B |
| Mar 2025 | $1.5B |
| Dec 2024 | $1.4B |
| Sep 2024 | $1.3B |
At each fiscal year end
Single quarter
Net margin, TTM
+13.3%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM STE
| FY Mar 2026 | +13.2% |
| FY Mar 2025 | +11.3% |
| FY Mar 2024 | n/a |
| FY Mar 2023 | n/a |
| FY Mar 2022 | +5.3% |
| Jun 2026 | +13.4% |
| Mar 2026 | +13.9% |
| Dec 2025 | +12.9% |
| Sep 2025 | +13.1% |
| Jun 2025 | +12.8% |
| Mar 2025 | +9.8% |
| Dec 2024 | +12.7% |
| Sep 2024 | +11.3% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$925.6M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM STE
| FY Mar 2026 | $972.4M |
| FY Mar 2025 | $778.0M |
| FY Mar 2024 | $613.0M |
| FY Mar 2023 | $395.0M |
| FY Mar 2022 | $397.2M |
| Jun 2026 | $279.6M |
| Mar 2026 | $245.2M |
| Dec 2025 | $199.5M |
| Sep 2025 | $201.3M |
| Jun 2025 | $326.4M |
| Mar 2025 | $189.9M |
| Dec 2024 | $243.6M |
| Sep 2024 | $148.9M |
At each fiscal year end
Single quarter
Debt to equity
0.26x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity STE
| FY Mar 2026 | 0.27x |
| FY Mar 2025 | 0.31x |
| FY Mar 2024 | 0.51x |
| FY Mar 2023 | 0.51x |
| FY Mar 2022 | 0.47x |
| Jun 2026 | 0.26x |
| Mar 2026 | 0.27x |
| Dec 2025 | 0.27x |
| Sep 2025 | 0.27x |
| Jun 2025 | 0.27x |
| Mar 2025 | 0.31x |
| Dec 2024 | 0.34x |
| Sep 2024 | 0.34x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.68x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt STE
| FY Mar 2026 | 0.69x |
| FY Mar 2025 | 0.56x |
| FY Mar 2024 | 0.30x |
| FY Mar 2023 | 0.25x |
| FY Mar 2022 | 0.22x |
| Jun 2026 | 0.68x |
| Mar 2026 | 0.69x |
| Dec 2025 | 0.67x |
| Sep 2025 | 0.69x |
| Jun 2025 | 0.66x |
| Mar 2025 | 0.56x |
| Dec 2024 | 0.53x |
| Sep 2024 | 0.49x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+11.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity STE
| FY Mar 2026 | +11.3% |
| FY Mar 2025 | +9.5% |
| FY Mar 2024 | +6.1% |
| FY Mar 2023 | +1.7% |
| FY Mar 2022 | +4.7% |
| Jun 2026 | +11.4% |
| Mar 2026 | +11.3% |
| Dec 2025 | +10.4% |
| Sep 2025 | +10.1% |
| Jun 2025 | +9.7% |
| Mar 2025 | +9.5% |
| Dec 2024 | +7.3% |
| Sep 2024 | +6.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+7.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets STE
| FY Mar 2026 | +7.5% |
| FY Mar 2025 | +5.8% |
| FY Mar 2024 | +3.5% |
| FY Mar 2023 | +1.0% |
| FY Mar 2022 | +2.7% |
| Jun 2026 | +7.6% |
| Mar 2026 | +7.5% |
| Dec 2025 | +6.9% |
| Sep 2025 | +6.7% |
| Jun 2025 | +6.3% |
| Mar 2025 | +5.8% |
| Dec 2024 | +4.4% |
| Sep 2024 | +4.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+9.9%
operating income after a 25.8% effective tax rate, over long-term 2026-06-30 plus current 2026-06-30 plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital STE
| FY Mar 2026 | +9.7% |
| FY Mar 2025 | +8.0% |
| FY Mar 2024 | +7.2% |
| FY Mar 2023 | +7.1% |
| FY Mar 2022 | +4.6% |
| Jun 2026 | +9.9% |
| Mar 2026 | +9.7% |
| Dec 2025 | +9.0% |
| Sep 2025 | +8.7% |
| Jun 2025 | +8.5% |
| Mar 2025 | +8.0% |
| Dec 2024 | +8.1% |
| Sep 2024 | +8.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+12.1%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed STE
| FY Mar 2026 | +11.8% |
| FY Mar 2025 | +9.0% |
| FY Mar 2024 | +8.3% |
| FY Mar 2023 | +7.7% |
| FY Mar 2022 | +5.8% |
| Jun 2026 | +12.1% |
| Mar 2026 | +11.8% |
| Dec 2025 | +10.7% |
| Sep 2025 | +10.3% |
| Jun 2025 | +9.9% |
| Mar 2025 | +9.0% |
| Dec 2024 | +8.9% |
| Sep 2024 | +8.6% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
29.02x
close 2026-10-26 over four quarters of diluted EPS, 2025-04-01 to 2026-03-31
P/E, trailing STE
| FY Mar 2026 | 27.89x |
| FY Mar 2025 | 36.62x |
| FY Mar 2024 | 58.85x |
| FY Mar 2023 | 178.77x |
| FY Mar 2022 | 101.16x |
| Jun 2026 | 26.55x |
| Mar 2026 | 27.89x |
| Dec 2025 | 35.41x |
| Sep 2025 | 35.60x |
| Jun 2025 | 36.84x |
| Mar 2025 | 36.62x |
| Dec 2024 | 43.64x |
| Sep 2024 | 55.37x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$23.8B
market value at close 2026-10-26 on 2026-08-04 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value STE
| FY Mar 2026 | $23.2B |
| FY Mar 2025 | $24.1B |
| FY Mar 2024 | $25.2B |
| FY Mar 2023 | $21.9B |
| FY Mar 2022 | $26.9B |
| Jun 2026 | $22.0B |
| Mar 2026 | $23.2B |
| Dec 2025 | $26.4B |
| Sep 2025 | $25.9B |
| Jun 2025 | $25.3B |
| Mar 2025 | $24.1B |
| Dec 2024 | $22.3B |
| Sep 2024 | $26.0B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+4.1%
TTM free cash flow over market value at close 2026-10-26
FCF yield STE
| FY Mar 2026 | +4.5% |
| FY Mar 2025 | +3.5% |
| FY Mar 2024 | +2.8% |
| FY Mar 2023 | +2.1% |
| FY Mar 2022 | +1.6% |
| Jun 2026 | +4.5% |
| Mar 2026 | +4.5% |
| Dec 2025 | +3.7% |
| Sep 2025 | +3.9% |
| Jun 2025 | +3.8% |
| Mar 2025 | +3.5% |
| Dec 2024 | +3.7% |
| Sep 2024 | +2.8% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
1.03x
P/E over trailing EPS growth of 28%: four quarters to 2026-03-31 against the four to 2025-03-31
PEG, trailing STE
| FY Mar 2026 | 0.99x |
| FY Mar 2025 | 0.59x |
| FY Mar 2024 | 0.23x |
| FY Mar 2023 | n/a |
| FY Mar 2022 | n/a |
| Jun 2026 | 0.94x |
| Mar 2026 | 0.99x |
| Dec 2025 | 0.68x |
| Sep 2025 | 0.61x |
| Jun 2025 | 0.60x |
| Mar 2025 | 0.59x |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2026-03 | 2025-03 | 2024-03 | 2023-03 | |
|---|---|---|---|---|
| Revenue | $5.9B | $5.5B | $5.1B | $5.0B |
| Gross profit | $2.6B | $2.4B | $2.2B | $2.0B |
| Operating income | $1.1B | $866.6M | $836.1M | $791.1M |
| Net income | $782.3M | $614.6M | $378.2M | $107.0M |
| EPS (diluted) | 7.93 | 6.20 | 3.81 | 1.07 |
| Operating cash flow | $1.3B | $1.1B | $973.3M | $756.9M |
| Cash | $439.6M | $171.7M | $207.0M | $208.4M |
| Long-term debt | $1.8B | $1.9B | $3.1B | $3.0B |
| Buybacks | $235.5M | $211.3M | $11.8M | $308.6M |
| Dividends paid | $241.8M | $219.9M | $200.6M | $183.5M |
SEC XBRL, fiscal years, as known on 2026-10-28
STE Stock Sonar score 6/7 axes
Find similar shapesCompareSTE ranks highest on profitability (72nd percentile) and financial health (71st), and lowest on insider conviction (14th), among Medical Devices peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
STE filings, in plain words
Are Steris insiders buying or selling STE?
In the 180 days to 2026-10-28, Steris insiders were net sellers, a net $2.5M across purchases and sales reported on Form 4, by 4 sellers.
Have members of Congress traded STE?
Yes. In the year to 2026-10-28, 2 House members disclosed buying STE and 3 House members disclosed selling it; the latest on record is a sale by Kevin Hern dated 2026-09-15.
Are there planned insider sales of STE?
Yes. 2 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $1.9M of stock; the latest, by Breeden Richard C, was filed 2026-08-18.
Read the full summary
In the 180 days to 2026-10-28, Steris insiders were net sellers of STE, a net $2.5M across purchases and sales reported on Form 4 by 4 sellers. None of the 5 insider sales was flagged as made under a Rule 10b5-1 plan. In the year to 2026-10-28, 2 members of Congress disclosed buying STE and 3 members disclosed selling it; the latest on record is a sale by Kevin Hern dated 2026-09-15. Insiders filed 2 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $1.9M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
